RAIN News and Press, Rain Therapeutics Inc. From 06/23/22

Gainers: F-star Therapeutics (FSTX) +57%. Valneva (VALN) +23%. Nutriband (NTRB) +16%. Rain Therapeutics (RAIN) +15%. uniQure (QURE) +15%. Losers: Applied Therapeutics (APLT) -25%. Mereo BioPharma Group (MREO) -14%. Rigel Pharmaceuticals (RIGL) ...

NEWARK, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics, today announced it will be presenting three posters highlighting its oral mouse double minute 2 (MDM2) inhibitor...

Rain Therapeutics press release (NASDAQ:RAIN): Q1 GAAP EPS of -$0.66. As of March 31, 2022, Rain had $123.2M in cash, cash equivalents and short-term investments. Rain anticipates that its quarter-end cash position will provide runway into the first half of 2024 which we expect the milademeta...

– Quarter-end cash position of $123.2 million provides ample cash runway into first half of 2024 – – Phase 3 MANTRA topline data expected earlier than previously guided, now in first half of 2023, with enrollment anticipated to be completed by end of 2022 &#...

NEWARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the first quarter ended March 31, 2022 and highlights of ...

NEWARK, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced a poster presentation and two trials in progress at the upcoming American Association for Canc...

Rain Therapeutics, Inc. (RAIN) Q4 2021 Earnings Conference Call March 3, 2022 4:30 PM ET Company Participants Kristy Grabowski - Director, Investor Relations Avanish Vellanki - Chief Executive Officer Richard Bryce - Chief Medical Officer Robert Doebele - Chief Scientific Officer Nelson Cabat...

Image source: The Motley Fool. Rain Therapeutics Inc. (NASDAQ: RAIN) Q4 2021 Earnings Call Mar 03, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Rain Therapeutics Inc. (RAIN) Q4 2021 Earnings Call Transcript

Rain Therapeutics press release (NASDAQ:RAIN): Q4 GAAP EPS of -$0.68 misses by $0.06. Q4 Net loss $51.4M For further details see: Rain Therapeutics GAAP EPS of -$0.68 misses by $0.06

– Quarter-end cash position of $140.2 million provides runway to complete all ongoing and planned clinical trials of milademetan, including an ample cash cushion for the Phase 3 MANTRA trial in liposarcoma – – Enrollment in both Phase 3 liposarcoma trial (MA...